Cures
Laufzeit: 01.01.2017 - 31.12.2018
Kurzfassung
A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)
Laufzeit: 01.01.2017 - 31.12.2018
A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)
